2003). or AChR were found to harbour antibodies against LRP4 (Higuchi et al. 2011; Cossins et al. 2012; Motomura & Higuchi, 2012; Pevzner et al. 2012; Richman, 2012; Zhang et al. 2012). There are also genetic disorders of neuromuscular transmission, called congenital myasthenic syndromes, that are caused by mutations in some of the key functional molecules, particularly the AChR and, much less frequently, MuSK (examined in Finlayson et al. in press). The NMJ is usually a very well characterised chemical synapse that was the focus for many early studies because of its accessibility. At the adult NMJ, the presynaptic motor axon terminal is usually directly opposed to the AChRs that are densely clustered at the top of postsynaptic membrane folds (Fig. ?(Fig.1).1). The high concentration of AChRs is crucial for efficient transmission of signal from your nerve to the muscle. Loss of AChRs, caused by the antibodies in AChR-MG, results in impaired signalling with endplate potential amplitudes that may not exceed the threshold for activation of the voltage-gated sodium channels that are responsible for the muscle action potential, leading to reduced neuromuscular transmission and muscle mass weakness. Open in a separate windows Fig. 1 (A) The neuromuscular junction illustrating the ACh located in synaptic vesicles and the high density of acetylcholine receptors (AChRs) clustered by RAPSN around the tops of the folds of postsynaptic membrane (grey). The AGRN/LRP4/MuSK/DOK7 pathway is essential for the clustering process. (B) The pathway and the action of MuSK antibodies can be studied by applying AGRN to C2C12 myotubes. In the presence of medium or healthy control serum samples (HC), AGRN induces clusters 8-Dehydrocholesterol of AChRs, recognized with fluorescent bungarotoxin. In the presence of MuSK antibodies, there are very few clusters created. Communication from your motoneuron to muscle mass is essential for correct formation, maintenance and function of the NMJ, and this includes both activity-dependent and activity-independent signalling. Although it is well known that MuSK plays an essential role in AChR clustering during development of the neuromuscular junction, it is not entirely obvious what role it plays in adult muscle mass. Even less well-understood is the retrograde signalling from your muscle to the motoneuron, which is also crucial in synapse differentiation and maintenance, and we believe is usually important for understanding how the antibodies to MuSK result in neuromuscular transmission failure. Here we will first describe what is known about MuSK-antibody myasthenia gravis (MuSK-MG) and the Rabbit polyclonal to PPP1R10 formation and maintenance of the neuromuscular junction, and then discuss the experimental evidence for the effects of MuSK antibodies, and how these results can be interpreted. AChR-MG and MuSK-MG In common MG (AChR-MG) most patients have antibodies against the AChR, and the pathogenic mechanisms of 8-Dehydrocholesterol AChR antibodies are well comprehended. About 10C15% of MG patients have no AChR antibodies, and of these so-called seronegative MG cases, 0C64% have antibodies to MuSK (Scuderi et al. 2002; 8-Dehydrocholesterol Sanders et al. 2003). Although 12 years have passed since the discovery of MuSK antibodies (Hoch et al. 2001), the main pathogenic mechanisms remain unclear C how do antibodies to a receptor tyrosine kinase lead to 8-Dehydrocholesterol AChR dysfunction and NMJ failure? But first we will describe briefly the similarities and differences between the two diseases. Formal epidemiology data for MuSK-MG are only available for two regions in Europe, with a prevalence of 2.9 per million in Greece and 1.9 per million in southern Holland (Niks et al. 2007; Carr et al. 2010), while the prevalence of AChR-MG is much higher than expected, 70C163 per million (Carr et al. 2010). The number of MuSK-MG patients reported from different myasthenia centres.